Media

January 9, 2025: ARES Trial of MaaT013 in GI-aGVHD Meets Primary End Point of GI-ORR – OncLive

Date : January 27, 2025

To see the article click here

January 8, 2025: MaaT Pharma touts ‘unprecedented’ Phase 3 efficacy of graft-versus-host disease treatment – Endpoints News

January 9, 2025: La biotech lyonnaise MaaT Pharma prouve les vertus du microbiote – Les Echos (French Only)